Spots Global Cancer Trial Database for Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Official Title: Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Study ID: NCT04319237

Conditions

Diffuse Large B Cell Lymphoma

Transformed Lymphoma

Interventions

Handgrip strength test

Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)

Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)

Neuropsychological Assessment - Color Trails

Neuropsychological Assessment -Stroop Color and Word Test

Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire

European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire

Quality of Life (EQ-5D-5L) Questionnaire

PROMIS Cognitive Function 4a Questionnaire

Comprehensive Score for Financial Toxicity (COST) measure

Study Description

Brief Summary: The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.

Detailed Description:

Keywords

Axi-cel therapy

CAR-T

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Moffitt Cancer Center, Tampa, Florida, United States

Contact Details

Name: Heather Jim, PhD

Affiliation: Moffitt Cancer Center

Role: PRINCIPAL_INVESTIGATOR

Name: Fred Locke, MD

Affiliation: Moffitt Cancer Center

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: